Bayer: Life cycle management not straightforward for Xarelto
Bayer: (NEUTRAL, Fair Value Under Review ())Life cycle management not straightforward for Xarelto
Bayer has announced two negative clinical results with Xarelto during ESC meeting. The first one is COMMANDER HF trial where Xarelto was not better than antiplatelet in secondary prevention of CV events in patients with heart failure. Therefore we have to reduce our EUR6.1bn peak sales for the drug by EUR600m. In the second study, MARINER, Xarelto was no better than placebo to prevent venous thromboembolism in medically-ill patients. As we didn't have estimates for this indication, this failure has no impact on our figures. After the loss of first round in glyphosate judiciary battle, these announcements add more and more clouds over Bayer’s future as we don't see an exciting pipeline to replace Xarelto and Eylea when they will lose their patents.
Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.